Benzinga | Aug 5, 2021 08:13AM EDT

Akebia Therapeutics Q2 EPS $(0.51) Misses $(0.32) Estimate, Sales $52.91M Beat $52.88M Estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.32) by 59.38 percent. This is a 15.91 percent decrease over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $52.91 million which beat the analyst consensus estimate of $52.88 million by 0.06 percent. This is a 41.30 percent decrease over sales of $90.14 million the same period last year.